Naldemedine

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Opioid-induced Constipation

Drug Information

Target Indication

Opioid-induced Constipation

Clinical Trial

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA2/18/2019

Rizmoic

Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.

Drug Science

Mechanism of action & safety profile

Developer

SGIOY

Shionogi

Related Pipeline

Atrophy

Cerebral Palsy

Atrophy

Atrophy

Healthcare-associated Pneumonia (HCAP)

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts